Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection

Benchmarks for protective immunity from infection or severe disease after SARS-CoV-2 vaccination are still being defined. Here, we characterized virus neutralizing and ELISA antibody levels, cellular immune responses, and viral variants in 4 separate groups: healthy controls (HCs) weeks (early) or m...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Han-Sol, Shapiro, Janna R., Sitaras, Ioannis, Woldemeskel, Bezawit A., Garliss, Caroline C., Dziedzic, Amanda, Sachithanandham, Jaiprasath, Jedlicka, Anne E., Caputo, Christopher A., Rousseau, Kimberly E., Thakar, Manjusha, Suwanmanee, San, Hauk, Pricila, Aliyu, Lateef, Majewska, Natalia I., Koley, Sushmita, Patel, Bela, Broderick, Patrick, Mosnaim, Giselle, Heath, Sonya L., Spivak, Emily S., Shenoy, Aarthi, Bloch, Evan M., Gniadek, Thomas J., Shoham, Shmuel, Casadevall, Arturo, Hanley, Daniel, Cox, Andrea L., Laeyendecker, Oliver, Betenbaugh, Michael J., Cramer, Steven M., Mostafa, Heba H., Pekosz, Andrew, Blankson, Joel N., Klein, Sabra L., Tobian, Aaron A.R., Sullivan, David, Gebo, Kelly A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983140/
https://www.ncbi.nlm.nih.gov/pubmed/35104245
http://dx.doi.org/10.1172/jci.insight.155944

Ejemplares similares

Ejemplares similares